Meeting
2021 ASCO Annual Meeting
Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Authors
Marwan Fakih
City of Hope Comprehensive Medical Center, Duarte, CA
Marwan Fakih , James M. Cleary , Yong Sang Hong , Tae-You Kim , Rachael A Safyan , Simon Allen , Lorna Bailey , Edward Cha , Christelle Lenain , Danny Lu , Jochen Schulze , Colby S. Shemesh , Stefan Zimmermann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03555149
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3559)
DOI
10.1200/JCO.2021.39.15_suppl.3559
Abstract #
3559
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.
First Author: Paul Eliezer Oberstein
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2015 ASCO Annual Meeting
An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).
First Author: Yasutoshi Kuboki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.
First Author: Nieves Martinez Lago